NDRG1 overexpression has also been shown to inhibit the downstream targets of EGFR signaling, e.g., MEK1/2 or ERK1/2, in pancreatic and prostate carcinoma cells (Dixon et al., 2013; Kovacevic et al., 2013, 2016). Here, NDRG1 is linked to prostate carcinoma.